Some sulfonamide drugs inhibit ATPase activity of heat shock protein 90: Investigation by docking simulation and experimental validation

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 26, Issue 5, 2011, Pages 603-609

  Sheikha, Ghassan Abu ^a   Al Sha'Er, Mahmoud A ^b   Taha, Mutasem O ^c  

^a AL ZAYTOONAH UNIVERSITY OF JORDAN   (Jordan)

^b ZARQA UNIVERSITY   (Jordan)

^c UNIVERSITY OF JORDAN   (Jordan)

Author keywords

Docking; Hsp90 ; PKa; Sulfonamides

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; HEAT SHOCK PROTEIN 90; SULFACETAMIDE; SULFADIAZINE; SULFADOXINE; SULFAFURAZOLE; SULFAMETHIZOLE; SULFATHIAZOLE; TORASEMIDE;

ARTICLE; ENERGY; ENZYME ACTIVITY; ENZYME INHIBITION; MOLECULAR DOCKING; PRIORITY JOURNAL; SIMULATION; VALIDATION STUDY;

ADENOSINE TRIPHOSPHATASES; BIOLOGICAL ASSAY; COLORING AGENTS; COMPUTER SIMULATION; ENZYME ACTIVATION; ENZYME INHIBITORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; ROSANILINE DYES; SULFAGUANIDINE; SULFONAMIDES;

EID: 80052837394     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2010.541394     Document Type: Article

References (66)

1. Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K, Giles FJ. Targeting HSP90 for cancer therapy. Br J Cancer 2009, 100, 1523-1529.
2. Chiosis G, Rodina A, Moulick K. Emerging Hsp90 inhibitors: from discovery to clinic. Anticancer Agents Med Chem 2006, 6, 1-8. (Pubitemid 43796652)
3. Dymock BW, Drysdale MJ, McDonald E, Workman P. Inhibitors of Hsp90 and other chaperones for the treatment of cancer. Expert Opin Ter Pat 2004, 14, 837-847. (Pubitemid 38868066)
4. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003, 3, 213-217. (Pubitemid 37443877)
5. Workman P. Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol Med 2004, 10, 47-51. (Pubitemid 38210022)
6. Chiosis G, Vilenchik M, Kim J, Solit D. Hsp90: the vulnerable chaperone. Drug Discov Today 2004, 9, 881-888. (Pubitemid 39314553)
7. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005, 5, 761-772. (Pubitemid 41400776)
8. Janin YL. Heat shock protein 90 inhibitors. A text book example of medicinal chemistry? J Med Chem 2005, 48, 7503-7512. (Pubitemid 41698792)
9. Chiosis G. Targeting chaperones in transformed systems-a focus on Hsp90 and cancer. Expert Opin Ter Targets 2006, 10, 37-50. (Pubitemid 43272410)
10. Kamal A, Boehm MF, Burrows FJ. Terapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med 2004, 10, 283-290. (Pubitemid 38725896)
11. Neckers L, Neckers K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics-an update. Expert Opin Emerg Drugs 2005, 10, 137-149. (Pubitemid 40293075)
12. Drysdale MJ, Brough PA, Massey A, Jensen MR, Schoepfer J. Targeting Hsp90 for the treatment of cancer. Curr Opin Drug Discov Devel 2006, 9, 483-495. (Pubitemid 44081157)
13. Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006, 13(Suppl. 1), S125-S135. (Pubitemid 46219254)
14. Xu W, Neckers L. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted efect on diverse cell signaling pathways of cancer cells. Clin Cancer Res 2007, 13, 1625-1629. (Pubitemid 46952925)
15. Workman P, Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 2007, 1113, 202-216. (Pubitemid 350015011)
16. Pearl LH, Prodromou C, Workman P. Te Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 2008, 410, 439-453. (Pubitemid 351429015)
17. Maloney A, Workman P. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. Expert Opin Biol Ter 2002, 2, 3-24.
18. Schulte TW, Neckers LM. Te benzoquinone ansamycin 17-allylamino-17- demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 1998, 42, 273-279. (Pubitemid 28393843)
19. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, Walton M, Lakhani S, Kaye S, Workman P, Judson I. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005, 23, 4152-4161. (Pubitemid 46211321)
20. Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, Adjei AA, Sloan J, Atherton P, Vasile V, Salazaar S, Adjei A, Croghan G, Erlichman C. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005, 23, 1078-1087. (Pubitemid 46202262)
21. Weigel BJ, Blaney SM, Reid JM, Safgren SL, Bagatell R, Kersey J, Neglia JP, Ivy SP, Ingle AM, Whitesell L, Gilbertson RJ, Krailo M, Ames M, Adamson PC. A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study. Clin Cancer Res 2007, 13, 1789-1793. (Pubitemid 46952947)
22. Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, Ma W, Wheler J, Rosen N, Norton L, Cropp GF, Johnson RG, Hannah AL, Hudis CA. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007, 25, 5410-5417. (Pubitemid 350232217)
23. Egorin MJ, Rosen DM, Wolf JH, Callery PS, Musser SM, Eiseman JL. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 1998, 58, 2385-2396. (Pubitemid 28252699)
24. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17- demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999, 91, 1940-1949.
25. Kaur G, Belotti D, Burger AM, Fisher-Nielson K, Borsotti P, Riccardi E, Tillainathan J, Hollingshead M, Sausville EA, Giavazzi R. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res 2004, 10, 4813-4821. (Pubitemid 38955535)
26. Ge J, Normant E, Porter JR, Ali JA, Dembski MS, Gao Y, Georges AT, Grenier L, Pak RH, Patterson J, Sydor JR, Tibbitts TT, Tong JK, Adams J, Palombella VJ. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem 2006, 49, 4606-4615. (Pubitemid 44162687)
27. Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, Pak RH, Ali JA, Dembski MS, Hudak J, Patterson J, Penders C, Pink M, Read MA, Sang J, Woodward C, Zhang Y, Grayzel DS, Wright J, Barrett JA, Palombella VJ, Adams J, Tong JK. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA 2006, 103, 17408-17413. (Pubitemid 44788982)
28. Chiosis G, Caldas Lopes E, Solit D. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents. Curr Opin Investig Drugs 2006, 7, 534-541. (Pubitemid 43891032)
29. DeBoer C, Meulman PA, Wnuk RJ, Peterson DH. Geldanamycin, a new antibiotic. J Antibiot 1970, 23, 442-447.
30. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995, 36, 305-315.
31. Neckers L, Schulte TW, Mimnaugh E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest New Drugs 1999, 17, 361-373. (Pubitemid 30135903)
32. Soga S, Shiotsu Y, Akinaga S, Sharma S V. Development of radicicol analogues. Curr Cancer Drug Targets 2003, 3, 359-369. (Pubitemid 37128322)
33. Chiosis G, Kang Y, Sun W. Discovery and development of purine-scafold Hsp90 inhibitors. Expert Opinion on Drug Discov 2008, 3, 99-114. (Pubitemid 351188347)
34. McDonald E, Jones K, Brough PA, Drysdale MJ, Workman P. Discovery and development of pyrazole-scafold Hsp90 inhibitors. Curr Top Med Chem 2006, 6, 1193-1203. (Pubitemid 44110930)
35. Taldone T, Gozman A, Maharaj R, Chiosis G. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 2008, 8, 370-374.
36. Messaoudi S, Peyrat JF, Brion JD, Alami M. Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem 2008, 8, 761-782.
37. Biamonte MA, Van de Water R, Arndt JW, Scannevin RH, Perret D, Lee WC. Heat shock protein 90: inhibitors in clinical trials. J Med Chem 2010, 53, 3-17.
38. Ganesh T, Tepchatri P, Li L, Du Y, Fu H, Snyder JP, Sun A. Synthesis and SAR study of N-(4-hydroxy-3-(2-hydroxynaphthalene-1-yl)phenyl)-arylsulfonamides: heat shock protein 90 (Hsp90) inhibitors with submicromolar activity in an in vitro assay. Bioorg Med Chem Lett 2008, 18, 4982-4987.
39. Barril X, Brough P, Drysdale M, Hubbard RE, Massey A, Surgenor A, Wright L. Structure-based discovery of a new class of Hsp90 inhibitors. Bioorg Med Chem Lett 2005, 15, 5187-5191. (Pubitemid 41463644)
40. Abel G, Connors TA, Goddard P, Hoellinger H, Nguyen-Hoang-Nam, Pichat L, Ross WC, Wilman DE. Cytotoxic sulphonamides designed for selective deposition in malignant tissue. Eur J Cancer 1975, 11, 787-793.
41. Casini A, Scozzafava A, Mastrolorenzo A, Supuran LT. Sulfonamides and sulfonylated derivatives as anticancer agents. Curr Cancer Drug Targets 2002, 2, 55-75. (Pubitemid 34627379)
42. Avila C, Hadden MK, Ma Z, Kornilayev BA, Ye QZ, Blagg BS. High-throughput screening for Hsp90 ATPase inhibitors. Bioorg Med Chem Lett 2006, 16, 3005-3008.
43. Lanzetta PA, Alvarez LJ, Reinach PS, Candia OA. An improved assay for nanomole amounts of inorganic phosphate. Anal Biochem 1979, 100, 95-97. (Pubitemid 10157636)
44. Christopher A, Boris A K, Brian S J. Development and optimization of a useful assay for determining Hsp90s inherent ATPase activity, Bioorg Med Chem 2006, 14, 1134-1142.
45. Venkatachalam CM, Jiang X, Oldfeld T, Waldman M. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J Mol Graph Model 2003, 21, 289-307. (Pubitemid 35441326)
46. Böhm HJ. Te development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J Comput Aided Mol Des 1994, 8, 243-256.
47. Muegge I. A knowledge-based scoring function for protein-ligand interactions: probing the reference state. Perspect Drug Discovery Des 2000, 20, 99-114.
48. Muegge I, Martin YC. A general and fast scoring function for protein-ligand interactions: a simplifed potential approach. J Med Chem 1999, 42, 791-804. (Pubitemid 29136170)
49. Muegge I. Efect of ligand volume correction on PMF scoring. J Comput Chem 2001, 22, 418-425. (Pubitemid 33640780)
50. Böhm HJ. Prediction of binding constants of protein ligands: a fast method for the prioritization of hits obtained from de novo design or 3D database search programs. J Comput Aided Mol Des 1998, 12, 309-323.
51. Jain AN. Scoring noncovalent protein-ligand interactions: a continuous diferentiable function tuned to compute binding afnities. J Comput Aided Mol Des 1996, 10, 427-440. (Pubitemid 126712439)
52. Rowlands YM, Newbatt CP, Laurence HP, Paul W, Wynne A. High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Analyt Biochem 2004, 327, 176-183.
53. Matts RL, Manjarrez JR. Assays for identifcation of Hsp90 inhibitors and biochemical methods for discriminating their mechanism of action. Curr Top Med Chem 2009, 9, 1462-1478.
54. Schulz-Gasch T, Stahl M. Scoring functions for protein-ligand interactions: a critical perspective. Drug Discov Today 2004, 1, 231-239. (Pubitemid 40201906)
55. Tame JR. Scoring functions: a view from the bench. J Comput Aided Mol Des 1999, 13, 99-108. (Pubitemid 29113101)
56. Krovat EM, Langer T. Impact of scoring functions on enrichment in docking-based virtual screening: an application study on renin inhibitors. J Chem Inf Comput Sci 2004, 44, 1123-1129.
57. Clark RD, Strizhev A, Leonard JM, Blake J F, Matthew JB. Consensus scoring for ligand/protein interactions. J Mol Graph Model 2002, 20, 281-295. (Pubitemid 34017546)
58. Miklos F. Consensus scoring for protein-ligand interactions. Drug Discov Today, 2006, 11, 421-428.
59. Song CM, Lim SJ, Tong JC. Recent advances in computer-aided drug design. Brief Bioinformatics 2009, 10, 579-591.
60. Jorgensen WL. Efcient drug lead discovery and optimization. Acc Chem Res 2009, 42, 724-733.
61. Leach AR, Shoichet BK, Peishof CE. Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. J Med Chem 2006, 49, 5851-5855. (Pubitemid 44484931)
62. Krovat EM, Langer T. Impact of scoring functions on enrichment in docking-based virtual screening: an application study on renin inhibitors. J Chem Inf Comput Sci 2004, 44, 1123-1129.
63. Klebe G. Virtual ligand screening: strategies, perspectives and limitations. Drug Discov Today 2006, 11, 580-594.
64. Krissinel, E. Crystal contacts as nature's docking solutions. J Comput Chem 2009, 31, 133-143.
65. Clarke's Analysis of Drugs and Poisons, Pharmaceutical Press, Monographs 2005.
66. a values of some substituted sulfonamides in acetonitrile-water binary mixtures by the UV-spectroscopy method. J Chem Eng Data 2009, 54, 3014-3021.